ICPT — Intercept Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $793.52m
- $713.07m
- $285.71m
Intercept Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Intercept Pharmaceuticals And Its Subsidiary Entered Into Two Separate Settlement Agreements With Apotex And Msn
Intercept Pharmaceuticals Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Intercept Pharmaceuticals, Unit Enters Into Settlement With Lupin Ltd, Lupin Pharmaceuticals
Brief: Intercept Pharmaceuticals- On Jan 24, Co, Unit Entered Into Settlement Agreement With Amneal EU, Limited, Amneal Pharmaceuticals Of New York, Llc
U.S. RESEARCH ROUNDUP-Concert Pharmaceuticals, Cyteir Therapeutics, LCI Industries
Brief: FDA Accepts Intercept's New Drug Application For Oca For The Treatment Of Pre-Cirrhotic Liver Fibrosis Due To Nash
Brief: Intercept, Unit Enters Into Agreement With Optimus Pharma, Optimus Drugs
H.C. Wainwright doubtful of Intercept Pharma's NASH drug getting FDA approval
U.S. STOCKS ON THE MOVE-Expion360, Atai Life Sciences, Intercept Pharmaceuticals
Intercept Pharma gains on resubmitting NASH drug for FDA review
Brief: Intercept Resubmits New Drug Application FDA For Obeticholic Acid In Patients With Liver Fibrosis Due To Nash
U.S. STOCKS ON THE MOVE-Tesla, Madrigal, Walt Disney
U.S. STOCKS ON THE MOVE-Madrigal, Disney, Forward Pharma
NASH drug developers Akero, 89Bio slump on rival's success
U.S. STOCKS ON THE MOVE-Regis Corp, Simon Property Group, Abiomed
Intercept Pharma rises on quarterly results beat
Intercept Pharmaceuticals Inc reports results for the quarter ended in September - Earnings Summary
Brief: Intercept Pharmaceuticals Reports Third Quarter 2022 Financial Results And Provides Business Update